Publications by authors named "Deborah Doss"

Claim this Profile
U
Understanding the Role and Clinical Management of Bridging Therapy During CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma.
Yi L Hwa, Deborah Doss, Patricia A Mangan, Michelle C Faber, Donna D Catamero

J Adv Pract Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma.
Beth Faiman, Deborah Doss, Kathleen Colson, Patricia Mangan, Tracy King

Clin J Oncol Nurs· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of health maintenance examinations and risk in myeloma patients.
Joseph D Tariman, Charise Gleason, Beth Faiman, Deborah Doss, Donna Catamero

Cancer Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Paul G Richardson, David Siegel, Rachid Baz, Susan L Kelley, Nikhil C Munshi, Deborah Doss

Blood· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Paul G Richardson, Jacob P Laubach, Robert L Schlossman, Irene M Ghobrial, Katherine C Redman, Deborah Doss

Eur J Haematol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sexual dysfunction in multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.
Tiffany A Richards, Page A Bertolotti, Deborah Doss, Emily J McCullagh,

Clin J Oncol Nurs· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Paul G Richardson, Edie Weller, Sagar Lonial, Andrzej J Jakubowiak, Sundar Jagannath, Deborah Doss

Blood· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Paul G Richardson, Jacob Laubach, Constantine Mitsiades, Robert L Schlossman, Deborah Doss

Oncology (Williston Park)· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Paul G Richardson, Edie Weller, Sundar Jagannath, David E Avigan, Melissa Alsina, Deborah Doss

J Clin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Paul G Richardson, Wanling Xie, Constantine Mitsiades, Asher A Chanan-Khan, Sagar Lonial, Deborah Doss

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding role of bortezomib in multiple myeloma: nursing implications.
Kathleen Colson, Deborah S Doss, Regina Swift, Joseph Tariman

Cancer Nurs· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.
Page Bertolotti, Elizabeth Bilotti, Kathleen Colson, Kathleen Curran, Deborah Doss

Clin J Oncol Nurs· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Sandra Rome, Deborah Doss, Kena Miller, Jeanne Westphal,

Clin J Oncol Nurs· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Paul G Richardson, Emily Blood, Constantine S Mitsiades, Sundar Jagannath, Steven R Zeldenrust, Deborah Doss

Blood· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in oral therapy in the treatment of multiple myeloma.
Deborah S Doss

Clin J Oncol Nurs· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Kathleen Colson, Deborah S Doss, Regina Swift, Joseph Tariman, Teri E Thomas

Clin J Oncol Nurs· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Paul Richardson, Robert Schlossman, Sundar Jagannath, Melissa Alsina, Raman Desikan, Deborah Doss

Mayo Clin Proc· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Paul G Richardson, Robert L Schlossman, Edie Weller, Teru Hideshima, Constantine Mitsiades, Deborah Doss

Blood· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.
Steven P. Treon, Constantine Mitsiades, Nicholas Mitsiades, Gloria Young, Deborah Doss

J Immunother (1991)· May 2001

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis